Работы, цитирующие эту работу

Работ: 3

Работа: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

1. CAR-T cell combination therapy: the next revolution in cancer treatment

   Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa +8

   Обзорная статьяCAR-T cell therapy researchCancer Cell International2022Цитирований: 2

   ABIABI:AkademIndex/openalex/2022.review-article.000004

2. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

   Muqadas Shahzadi, Hamad Rafique, Ahmad Waheed +4

   Обзорная статьяCAR-T cell therapy researchTherapeutic Advances in Vaccines and Immunotherapy2024Цитирований: 1

   ABIABI:AkademIndex/openalex/2024.review-article.000014

3. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   СтатьяCAR-T cell therapy researchJournal of Hematology & Oncology2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.article.000083